Merck & Co.MRKEarnings & Financial Report
Merck & Co., Inc. is an American multinational pharmaceutical company headquartered in Rahway, New Jersey. The company does business as Merck Sharp & Dohme or MSD outside the United States and Canada. The company is ranked fourth on the list of largest biomedical companies by revenue.
MRK Q3 2025 Key Financial Metrics
売上高
$17.3B
粗利益
$13.4B
営業利益
N/A
純利益
$5.8B
粗利益率
77.7%
営業利益率
N/A
純利益率
33.5%
前年比成長
3.7%
EPS
$2.32
資金フロー
Merck & Co. Q3 2025 Financial Summary
Merck & Co. reported revenue of $17.3B for Q3 2025, with a net profit of $5.8B (33.5% margin). Cost of goods sold was $3.9B, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $17.3B |
|---|---|
| Net Profit | $5.8B |
| Gross Margin | 77.7% |
| Operating Margin | N/A |
| Report Period | Q3 2025 |
Merck & Co. Annual Revenue by Year
Merck & Co. annual revenue history includes year-by-year totals (for example, 2024 revenue was $64.2B).
| Year | Annual Revenue |
|---|---|
| 2024 | $64.2B |
| 2023 | $60.1B |
| 2022 | $59.3B |
損益計算書
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| 売上高 | $14.63B | $15.78B | $16.11B | $16.66B | $15.62B | $15.53B | $15.81B | $17.28B |
| 前年比成長 | 5.8% | 8.9% | 7.2% | 4.4% | 6.8% | -1.6% | -1.9% | 3.7% |
貸借対照表
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| 総資産 | $106.67B | $105.85B | $112.63B | $117.53B | $117.11B | $115.12B | $117.52B | $129.55B |
| 総負債 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| 株主資本 | $37.58B | $40.36B | $43.58B | $44.50B | $46.31B | $48.34B | $48.99B | $51.85B |
キャッシュフロー
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| 営業CF | $246.0M | $3.09B | $5.64B | $9.29B | $3.45B | $2.50B | $3.29B | $7.82B |
Other Health Care Companies
BMY
Bristol Myers Squibb
売上高
$12.5B
純利益
$1.1B
JNJ
Johnson & Johnson
売上高
$24.6B
純利益
$5.1B
LLY
Lilly (Eli)
売上高
$19.3B
純利益
$6.6B
PFE
Pfizer
売上高
$16.7B
純利益
$3.5B
VTRS
Viatris
売上高
$3.7B
純利益
N/A
ZTS
Zoetis
売上高
$2.4B
純利益
$603.0M
ABT
Abbott Laboratories
売上高
$11.4B
純利益
$1.6B
ABBV
AbbVie
売上高
$15.8B
純利益
$186.0M
A
Agilent Technologies
売上高
$1.9B
純利益
$434.0M
ALGN
Align Technology
売上高
$995.7M
純利益
$56.8M